SciELO - Scientific Electronic Library Online

 
vol.15 número3Frequência e fatores relacionados ao índice tornozelo-braquial aberrante em diabéticosPrevenção de tromboembolismo venoso em hospital com perfil oncológico: como melhorá-la? índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Jornal Vascular Brasileiro

versão impressa ISSN 1677-5449versão On-line ISSN 1677-7301

Resumo

KOVALESKI, Elenara Simoni et al. Pharmacotherapeutic profile of obese patients during the postoperative period after bariatric surgery. J. vasc. bras. [online]. 2016, vol.15, n.3, pp.182-188.  Epub 26-Set-2016. ISSN 1677-5449.  http://dx.doi.org/10.1590/1677-5449.002016.

Background

Obesity can be associated with diseases such as diabetes, arterial hypertension and dyslipidemia. Bariatric surgery is one of the most effective treatments available, reducing both weight and comorbidities.

Objective

To evaluate the metabolic and pharmacotherapeutic profile of obese patients after bariatric surgery.

Methods

This is a retrospective, cross-sectional, observational study conducted at a hospital located in the city of Porto Alegre, RS, Brazil, based on analysis of the medical records for 70 patients who underwent bariatric surgery covering periods spanning from 2 months prior to more than 6 months after their bariatric surgery. Statistical analysis was conducted using SPSS 17.0®.

Results

Initial arterial blood pressure was 130/85 mmHg, 6 months after surgery it was 120/80 mmHg (p < 0.01). The metabolic profile 2 months before surgery was as follows: HDL was 34 mg/dL, total cholesterol was 195.07 ± 40.17 mg/dL, LDL was 118.22 ± 41.28 mg/dL, triglycerides were 141.09 ± 43.39 mg/dL, and fasting glycemia was 90 mg/dL. The same figures 6 months after surgery were 43 mg/dL, 133.67 ± 28.14 mg/dL, 65.53 ± 24.3 mg/dL, 104.41 ± 29.6 mg/dL, and 77 mg/dL, respectively (p < 0.01). Use of medications 2 months before surgery was as follows: 41% were on antihypertensives, 39% on hypolipidemics, 10% on oral hypoglycemics, and 97% were on nutritional supplements. These percentages 6 months after surgery had changed to 21%, 19%, 9% and 99%, respectively.

Conclusions

This study illustrates that bariatric surgery for obese patients with comorbidities was successful, demonstrating improvements in their metabolic profile and reductions in use of medications used to treat comorbidities.

Palavras-chave : obesity; bariatric surgery; attention pharmaceutical; pharmacotherapy.

        · resumo em Português     · texto em Português | Inglês     · Português ( pdf ) | Inglês ( pdf )